Cookie Consent by Free Privacy Policy website Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring
october 04, 2018 - Philips

Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring

Press release available only in original language. 

  • The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on #philips #healthsuite digital platform
  • The combination of #ypsomed connected self-medication devices with Philips’ #healthsuite digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes

Burgdorf, Switzerland and Eindhoven, the Netherlands – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based #healthsuite digital platform. To this end, the companies have signed a memorandum of understanding and aim to sign the definitive agreements in the fourth quarter of 2018. 

With the new SmartServices™, #ypsomed aims to extend its medical device business, by providing a new turnkey digital solution for medication adherence monitoring and smart device management to its pharmaceutical customers. Ypsomed’s SmartServices™ will be enabled by Philips’ #healthsuite digital platform, a cloud-based platform which was purpose-built for the complex challenges in healthcare, and provides tools and services focused on ease-of-integration, digital lifecycle management, and end-to-end security. The new digital services aim to address a wide range of device-oriented challenges and support self-medication services for patients across chronic disease states, such as diabetes, multiple sclerosis and rheumatoid arthritis.

Further information in the press release to download